Abstract Treatment resistant schizophrenia (TRS) refers to the significant proportion of
schizophrenia patients who continue to have symptoms and poor outcomes despite …

Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third
of patients do not show adequate improvement in positive symptoms with non-clozapine …

Background Schizophrenia is a highly heterogeneous disorder, and around a third of
patients are treatment-resistant. The only evidence-based treatment for these patients is …

Although treatment-resistant schizophrenia (TRS) was described 50 years ago 1 and has a
gold standard treatment with clozapine based on well-defined criteria, 2 there is still a matter …

Background In terms of antipsychotic treatment response, patients with schizophrenia can
be classified into three groups: 1) treatment resistant to both non-clozapine (non-CLZ) …

Treatment-resistant schizophrenia, affecting approximately 20–30% of patients with
schizophrenia, has a high burden both for patients and healthcare services. There is a need …

Background: Glutathione is among the important antioxidants to prevent oxidative stress.
However, the relationships between abnormality in the glutathione system and …

Approximately one-third of patients with schizophrenia have treatment-resistant
schizophrenia (TR-SCZ), which is a condition characterized by suboptimal response to …

Background: Roughly 30% of schizophrenia patients fail to respond to at least two
antipsychotic trials. Psychosis has been traditionally considered to be poorly sensitive to …

The aim of this study was to compare cognitive performance between schizophrenia patients
with and without treatment resistance (TRS and non-TRS patients) taking into account …